Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Product/Service, Trade Show, Webcast

Kala Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference


Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFYtm mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present a corporate overview on Wednesday, January 15, 2020 at 11:30 a.m. PT (2:30 p.m. ET).

To access a live webcast and subsequent archived recording of the presentation, please visit the "Investors & Media" section on the Kala website at http://kalarx.com.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFYtm mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the August 2018 FDA approval of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of inflammation and pain following ocular surgery and its lead product candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.


These press releases may also interest you

at 00:01
In the face of the latest and more contagious variant of COVID-19, Delta, a bipartisan group of leaders and public health experts, in an open letter to CEOs provided by the COVID Collaborative, are calling on private sector employers to require...

4 aoû 2021
Nathan Sassover, Founder / CEO of World Cancer Institute Inc. today announced "further clinical developments in enlarging our targeted medical objectives which originated in 2008 and have evolved to a multiplicity of protocols which continue to be...

4 aoû 2021
The probiotic cosmetic products market in the Personal Products industry is poised to grow by USD 492.91 million during 2021-2025. Technavio's latest market research report estimates that the probiotic cosmetic products market will be progressing at...

4 aoû 2021
The food recall warning issued on August 3, 2021 has been updated to include additional information on how the affected product may have been sold. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food...

4 aoû 2021
The boil water order issued by Alberta Health Services on July 29 has been lifted for the remaining areas of Rundleview and Homesteads. These areas add to the following locations that have been cleared for regular water service over the past few...

4 aoû 2021
Shenzhen, Guangdong, China, and Singapore ? Huawei Technologies Co. Ltd. (hereinafter, Huawei) and Plano Pte. Ltd. (hereinafter, Plano) today announced their partnership to address the global problem of myopia. Through this partnership, Huawei and...



News published on 8 january 2020 at 08:05 and distributed by: